Showing 1901-1910 of 2657 results for "".
- Nacuity Pharmaceuticals Granted FDA Fast Track Designation for NPI-001 Tablets for RPhttps://modernod.com/news/nacuity-pharmaceuticals-granted-fda-fast-track-designation-for-npi-001-tablets-for-retinitis-pigmentosa/2482625/Nacuity Pharmaceuticals announced that the FDA has granted Fast Track Designation to NPI-001 (N-acetylcysteine amide) tablets, Nacuity’s proprietary investigational therapy for the treatment of patients with retinitis pigmentosa (RP). A drug may receive Fast Track designation
- Visible Genomics Wins 2025 AMD Genetic Testing Company of the Year Awardhttps://modernod.com/news/visible-genomics-wins-2025-amd-genetic-testing-company-of-the-year-award/2482619/Visible Genomics, a provider of genetic testing solutions for severe ocular diseases, was named 'Life Sciences Review AMD Genetic Testing Company of the Year 2025.' This award recognizes the company’s innovative contributions to proactive care for advanced age-related macular degene
- PulseSight Therapeutics Initiates Clinical Plan of PST-611 Transferrin Vectorized Therapy for Dry AMD/GAhttps://modernod.com/news/pulsesight-therapeutics-initiates-clinical-plan-of-pst-611-transferrin-vectorized-therapy-for-dry-amdga/2482615/PulseSight Therapeutics SAS announced it has submitted a clinical trial authorization (CTA) to Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) for a phase 1 trial (PST-611-CT1) assessing the safety
- Sling Therapeutics Announces Positive Topline Results from Phase 2b/3 LIDS Trial of Linsitinib in Patients with TEDhttps://modernod.com/news/sling-therapeutics-announces-positive-topline-results-from-phase-2b3-lids-trial-of-oral-small-molecule-linsitinib-in-patients-with-ted/2482614/Sling Therapeutics announced topline efficacy and safety data from the phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe Thyroid Eye Disease (TED). Linsitinib, Sling’s lead product candidate, is an oral small molecule, taken twice-daily
- FDA Approves Zeiss MEL 90 Excimer Laserhttps://modernod.com/news/fda-approves-zeiss-mel-90-excimer-laser/2482611/Zeiss has received FDA approval for the MEL 90, giving the excimer laser technology simultaneous approval for all three major indications: myopia, hyperopia, and mixed astigmatism. The Zeiss MEL 90 fully integrates into the company's Corneal Refractive Workflow,
- Tenpoint Therapeutics Announces Positive Topline Data from Phase 3 Study of Brimochol PF for Presbyopiahttps://modernod.com/news/tenpoint-therapeutics-announces-positive-topline-data-from-phase-3-pivotal-study-of-brimochol-pf-for-the-treatment-of-presbyopia/2482609/Tenpoint Therapeutics reported positive topline results from BRIO-II, the company’s second phase 3 pivotal trial. BRIO-II met the prespecified primary endpoints agreed upon with the FDA, and European Medicines Agency (EMA), and the UK Medicines and Healthcare products Regulatory Agency
- Dry Eye Institute Launches 'DEI On Demand' and Kicks Off Inaugural Road Eventhttps://modernod.com/news/dry-eye-institute-launches-dei-on-demand-and-kicks-off-inaugural-road-event/2482605/The Dry Eye Institute (DEI), an educational program for optometrists and ophthalmologists specializing in advanced dry eye care, has announced that for the first time, the institute’s curriculum is now available online through 'DEI On Demand.' DEI also announced that
- Atsena Therapeutics Initiates Part B of Phase 1/2 Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-initiates-part-b-of-phase-12-clinical-trial-evaluating-gene-therapy-atsn-201-to-treat-x-linked-retinoschisis/2482602/Atsena Therapeutics announced the initiation of Part B of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a gene therapy product candidate, leverages AAV.SPR, the company’s n
- Topcon Healthcare Appoints Christian Odaker as Chief Technology Officerhttps://modernod.com/news/topcon-healthcare-appoints-christian-odaker-as-chief-technology-officer/2482599/Topcon Healthcare announced the appointment of Christian Odaker, PhD, to the role of Chief Technology Officer (CTO). Dr. Odaker willsupport the company's 'Healthcare from the Eye' initiative, which leverages AI-powered disease detection and management using da
- Vabysmo Prefilled Syringe (PFS) Approved in the EUhttps://modernod.com/news/vabysmo-prefilled-syringe-pfs-approved-in-the-eu-for-three-retinal-conditions/2482582/The European Medicines Agency (EMA) has approved Roche's Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion